The Health Economics of Genomic Technologies: A Growing Evidence Base on Value.
作者信息
Buchanan James, Goranitis Ilias, Weymann Deirdre
机构信息
Health Economics and Policy Research Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
National Institute for Health Research, Barts Biomedical Research Centre, Queen Mary University of London, London, UK.
出版信息
Appl Health Econ Health Policy. 2025 May;23(3):331-335. doi: 10.1007/s40258-025-00970-z. Epub 2025 Apr 28.
Abstract
摘要
相似文献
1
The Health Economics of Genomic Technologies: A Growing Evidence Base on Value.
Appl Health Econ Health Policy. 2025 May;23(3):331-335. doi: 10.1007/s40258-025-00970-z. Epub 2025 Apr 28.
2
Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward.
Pharmacoeconomics. 2023 Jul;41(7):787-802. doi: 10.1007/s40273-022-01231-w. Epub 2023 Mar 11.
3
Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies.
J Pers Med. 2019 May 21;9(2):28. doi: 10.3390/jpm9020028.
4
A health services research agenda for cellular, molecular and genomic technologies in cancer care.
Public Health Genomics. 2009;12(4):233-44. doi: 10.1159/000203779. Epub 2009 Feb 20.
5
Economics of genomic testing for women with breast cancer.
Am J Manag Care. 2013 Dec;19(12):1024-31.
6
Paving the path for implementation of clinical genomic sequencing globally: Are we ready?
Health Aff Sch. 2024 Apr 29;2(5):qxae053. doi: 10.1093/haschl/qxae053. eCollection 2024 May.
7
Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
Value Health. 2012 Dec;15(8):1162-71. doi: 10.1016/j.jval.2012.05.006. Epub 2012 Sep 7.
8
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.
9
Health care in the developing world: the role of economists and economics.
Soc Sci Med. 1983;17(24):2007-15. doi: 10.1016/0277-9536(83)90141-7.
10
An international consensus panel on the potential value of Digital Surgery.
BMJ Open. 2024 Sep 5;14(9):e082875. doi: 10.1136/bmjopen-2023-082875.
本文引用的文献
1
The Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review.
Appl Health Econ Health Policy. 2025 May;23(3):359-393. doi: 10.1007/s40258-025-00949-w. Epub 2025 Mar 29.
2
Beyond the Diagnosis: Valuing Genome-Wide Sequencing for Rare Disease Diagnosis Using Contingent Valuation.
Appl Health Econ Health Policy. 2025 May;23(3):425-439. doi: 10.1007/s40258-025-00948-x. Epub 2025 Mar 14.
3
Cost-Utility Analysis of Genomic Profiling in Directing Targeted Therapy in Advanced NSCLC in Thailand.
Appl Health Econ Health Policy. 2025 May;23(3):479-491. doi: 10.1007/s40258-025-00950-3. Epub 2025 Feb 7.
4
Approaches to Incorporation of Preferences into Health Economic Models of Genomic Medicine: A Critical Interpretive Synthesis and Conceptual Framework.
Appl Health Econ Health Policy. 2025 May;23(3):337-358. doi: 10.1007/s40258-025-00945-0. Epub 2025 Jan 20.
5
Australian Preferences for Prenatal Screening: A Discrete Choice Experiment Comparing Metropolitan and Rural/Regional Areas.
Appl Health Econ Health Policy. 2025 May;23(3):493-506. doi: 10.1007/s40258-024-00938-5. Epub 2025 Jan 17.
6
Genetic Test Utilization and Cost among Families of Children Evaluated for Genetic Conditions: An Analysis of USA Commercial Claims Data.
Appl Health Econ Health Policy. 2025 May;23(3):519-530. doi: 10.1007/s40258-024-00942-9. Epub 2025 Jan 8.
7
Exome Sequencing in the Diagnostic Pathway for Suspected Rare Genetic Diseases: Does the Order of Testing Affect its Cost-Effectiveness?
Appl Health Econ Health Policy. 2025 May;23(3):453-466. doi: 10.1007/s40258-024-00936-7. Epub 2024 Dec 30.
8
Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.
Appl Health Econ Health Policy. 2025 May;23(3):467-478. doi: 10.1007/s40258-024-00932-x. Epub 2024 Dec 2.
9
Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies.
Appl Health Econ Health Policy. 2025 May;23(3):507-517. doi: 10.1007/s40258-024-00927-8. Epub 2024 Nov 13.
10
Microcosting genomics: Challenges and opportunities.
Genet Med. 2025 Feb;27(2):101310. doi: 10.1016/j.gim.2024.101310. Epub 2024 Nov 7.
Zotero 插件